Profile

William Jeffrey Petty, M.D.Wake Forest Baptist Health

Doctor Rating

4.7 out of 5

117 Ratings
20 Comments
 

William Jeffrey Petty, M.D.

Associate Professor,

Clinical Interests

Lung Cancer, Thoracic Cancer

Contact Information

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-713-5440
Department: 336-716-4464

Insurance Accepted »

Media Medical Expert »

Education & Training

  • B.A., Harvey Mudd College, 1994
  • M.D., University of North Carolina School of Medicine, 1998
  • Residency, Duke University Medical Center, 2001
  • Fellowship, Dartmouth Medical School, 2003

Board Certifications

  • American Board of Internal Medicine, Medical Oncology

Memberships

  • Am Assn Of Cancer Research
  • Amer Coll Of Chest Physicians
  • Am Soc of Clinical Oncology

NPI Number

  • 1164406690
William Jeffrey Petty, M.D.

Doctor Rating

4.7 out of 5

117 Ratings
20 Comments
 

William Jeffrey Petty, M.D.

Associate Professor, Hematology & Oncology
Cancer Biology

Research Interests

Radiotherapy, Conformal; Carcinoma, Non-Small-Cell Lung; Astrocytoma; Protein Kinase Inhibitors; Lung Neoplasms
More »

Contact Information

Academic: 336-713-4392 | Department: 336-716-4464

Media Medical Expert »

Recent Publications

Image guided radiation therapy may result in improved local control in locally advanced lung cancer patients. Kilburn JM, Soike MH, Lucas JT, Ayala-Peacock D, Blackstock W, Isom S, Kearns WT, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ.. Pract Radiat Oncol. 2016;6(3):e73-e80.

Is a clinical target volume (CTV) necessary in the treatment of lung cancer in the modern era combining 4-D imaging and image-guided radiotherapy (IGRT)?. Kilburn JM, Lucas JT, Soike MH, Ayala-Peacock DN, Blackstock AW, Hinson WH, Munley MT, Petty WJ, Urbanic JJ.. Cureus. 2016;8(1):e466.

Hemolytic anemia in two patients with glioblastoma multiforme: a possible interaction between vorinostat and dapsone. Lewis JA, Petty WJ, Harmon M, Peacock JE, Valente K, Owen J, Pirmohamed M, Lesser GJ.. J Oncol Pharm Pract. 2015;21(3):220-223.

Low-dose CT lung cancer screening practices and attitudes among primary care providers at an academic medical center. Lewis JA, Petty WJ, Tooze JA, Miller DP, Chiles C, Miller AA, Bellinger C, Weaver KE.. Cancer Epidemiol Biomarkers Prev. 2015;24(4):664-670.

Clinical perspective on PROSE: does VeriStrat testing improve selection of second-line treatment for patients with non-small cell lung cancer? [editorial]. Ruiz J, Petty WJ.. Ann Transl Med. 2015;3(3):31.

Clinical implications of RAR-beta methylation in cancer tissue and peripheral blood leukocytes of patients with lung cancer [abstract]. Ansley KC, Dotson T, Hawkins G, Petty WJ.. Int J Mol Med. 2015;36(Suppl 1):S103.

Robotic thoracic surgery for elderly patients with non-small cell lung cancer [abstract]. Hughes RT, Dipasquale VM, Grant SC, Lally BE, Petty WJ, Proto A, Wudel LJ.. J Thorac Oncol. 2015;10(9 Suppl 2):S561.

Molecular subtyping in advanced non-small cell lung cancer, a minimally invasive strategy with small volume fine needle aspirates [abstract]. Hansen K, Miller L, Dotson T, Bellinger C, Parks G, Cappellari J, Clark H, Howard C, Bolemon B, Petty WJ, Craddock L, Ruiz J.. J Thorac Oncol. 2015;10(9 Suppl 2):S701.

Nodal staging via robotic-assisted thoracic surgery for clinical stage I non-small cell lung cancer [abstract]. Dipasquale VM, Hughes RT, Grant S, Lally BE, Petty WJ, Proto A, Wudel LJ.. J Thorac Oncol. 2015;10(9 Suppl 2):S333.

Growing a thoracic oncology program [abstract]. Bellinger CR, Hovda J, Petty WJ, Ruiz J, Dotson TL, Wudel LJ.. Am J Respir Crit Care Med. 2015;191():A5086.

Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer. Kilburn JM, Lester SC, Lucas JT Jr, Soike MH, Blackstock AW, Kearns WT, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ.. J Thorac Oncol. 2014;9(4):572-576.

Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment. Kilburn JM, Kuremsky JG, Blackstock AW, Munley MT, Kearns WT, Hinson WH, Lovato JF, Miller AA, Petty WJ, Urbanic JJ.. Radiother Oncol. 2014;110(3):505-510.

Which lung tumors shrink during fractionated radiation and how does this influence outcome?: Appropriately selecting tumor and treatment characteristics for adaptive radiation therapy protocols [abstract]. Kilburn JM, Lucas JT, Soike MH, Ayala-Peacock D, Kuremsy JG, Blackstock A, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 1):S641-S642.

An evaluation of toxicity using accumulated total dose based on EQD2 for thoracic reirradiation incorporating at least 1 course of SBRT [abstract]. Lester SC, Kilburn JM, Lucas JT, Soike MH, Blackstock AW, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 1):S640-S641.

Low-dose CT lung cancer screening practices and attitudes among primary care providers at an academic medical center [abstract]. Lewis J, Petty WJ, Tooze JA, Miller DP, Chiles C, Miller AA, Weaver KE.. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 5):S7-S8.

Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer. Petty WJ, Laudadio J, Brautnick L, Lovato J, Dotson T, Streer NP, Weaver KE, Miller AA.. Int J Oncol. 2013;43(6):2057-2063.

Stereotactic body radiation therapy (SBRT) and image guided accelerated hypofractionated radiation therapy (IGAHRT) for the treatment of oligometastatic cancers [abstract]. Ayala-Peacock DN, Blackstock AW, Kearns WT, Hinson WH, Munley MT, Miller AA, Petty WJ, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S567-S568.

Is a clinical target volume (CTV) necessary in treatment of thoracic malignancies treated in the modern era combining 4-D imaging and image guided radiation therapy (IGRT)? [abstract]. Kilburn JM, Lucas JT, Soike MH, Ayala-Peacock D, Blackstock AW, Kearns WT, Hinson WH, Miller AA, Petty WJ, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S549.

Multiple courses of thoracic radiation therapy (XRT) using stereotactic body radiation therapy (SBRT) as the first or second course of treatment for tumors outside the original high-dose region [abstract]. Kilburn JM, Lester SC, Lucas JT, Blackstock AW, Kearns WT, Hinson WH, Munley MT, Miller AA, Petty WJ, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S36.

Salvage radiation for mediastinal relapse after treatment with accelerated hypofractionated radiation therapy (AHRT) or stereotactic body radiation therapy (SBRT) for stage I/II NSCLC [abstract]. Lester SC, Kilburn JM, Lucas JT, Munley MT, Blackstock AW, Kearns WT, Hinson WH, Miller AA, Petty WJ, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S543-S544.

Image guided radiation therapy results in mproved local control in lung cancer patients treated with fractionated radiation therapy for stage IIB-IIIB disease [abstract]. Soike M, Kilburn JM, Lucas JT, Ayala-Peacock D, Blackstock AW, Kearns WT, Hinson WH, Miller AT [sic] [Miller AA], Petty WJ, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S547-S548.

Tumor histology predicts patterns of failure and survival in patients with brain metastases from lung cancer treated with gamma knife radiosurgery. Kuremsky JG, Urbanic JJ, Petty WJ, Lovato JF, Bourland JD, Tatter SB, Ellis TL [deceased], McMullen KP, Shaw EG, Chan MD.. Neurosurgery. 2013;73(4):641-647.

Reverse translation of phase I biomarker findings links the activity of angiotensin-(1-7) to repression of hypoxia inducible factor-1alpha in vascular sarcomas. Petty WJ, Aklilu M, Varela VA, Lovato J, Savage PD, Miller AA.. BMC Cancer. 2012;12():404.

Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial. Socinski MA, Stinchcombe TE, Moore DT, Gettinger SN, Decker RH, Petty WJ, Blackstock AW, Schwartz G, Lankford S, Khandani A, Morris DE.. J Clin Oncol. 2012;30(32):3953-3959.

Thoracic reirradiation in patients with stereotactic body radiation therapy (SBRT) as first or second course of treatment [abstract]. Kilburn JM, Kuremsky JG, Blackstock AW, Kearns WT, Hampton CJ, Hinson WH, Miller AA, Petty WJ, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2012;84(3 Suppl):S604.

Hypofractionated radiation therapy for stage I and II non-small cell lung cancer [abstract]. Kuremsky JG, Petty WJ, Miller A, Hinson WH, Hampton CJ, Blackstock AW, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2012;84(3 Suppl):S153-S154.

Thoracic re-irradiation in patients with stereotactic body radiotherapy (SBRT) as first or second course of treatment [abstract]. Kilburn KM, Kuremsky JG, Blackstock AW, Kearns WT, Hampton CJ, Hinson WH, Miller AA, Petty WJ, Urbanic JJ.. J Thorac Oncol. 2012;7(9 Suppl 4):S253-S254.

Hypofractionated radiotherapy for stage I and II non-small cell lung cancer [abstract]. Kuremsky JG, Petty WJ, Miller A, HInson WH, Hampton CJ, Blackstock AW, Urbanic JJ.. J Thorac Oncol. 2012;7(9 Suppl 4):S230.

Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC) [abstract]. Stinchcombe T, Socinski MA, Moore DT, Gettinger SN, Decker RH, Petty WJ, Blackstock AW, Schwartz G, Lankford S, Morris DE.. J Clin Oncol. 2011;29(Suppl):abstr 7016.

Microarray gene expression patterns recapitulated on a clinically tractable diagnostic platform using breast and lung cancer formalin-fixed paraffin-embedded tissues [abstract]. Ruiz J, Chou J, Geisinger KR, Schoppe CH, Miller AA, Willingham MC, Petty WJ, Bolemon BH, Miller LD.. J Clin Oncol. 2011;29(Suppl):e21027.

Phase II study of dose-dense chemotherapy followed by dose-intense erlotinib for initial treatment of metastatic NSCLC [abstract]. Waller LL, Miller AA, Streer NP, Lovato JF, Petty WJ.. J Clin Oncol. 2011;29(Suppl):abstr 7601.

High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer. Petty WJ, Voelzke WR, Urbanic JJ, Varela VA, Waller LL, Swift CB, Graham RM, Memoli VA, Dragnev KH.. Lung Cancer. 2011;74(3):384-391.

A role for angiotensin converting enzyme inhibition in lung cancer chemoprevention [abstract]. Petty WJ, Varela VA, Swift CB, Urbanic JJ.. Int J Mol Med. 2011;28(Suppl 1):S68.

Tumor histology predicts patterns of failure and survival in patients with lung cancer treated with gamma knife radiosurgery [abstract]. Kuremsky JG, Urbanic JJ, Petty WJ, Lovato JF, Bourland JD, Tatter SB, Ellis TL, McMullen KP, Shaw EG, Chan MD.. Int J Radiat Oncol Biol Phys. 2011;81(2 Suppl):S595.

A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer. Center B, Petty WJ, Ayala D, Hinson WH, Lovato J, Capellari J [sic] [Cappellari J], Oaks T, Miller AA, Blackstock AW.. J Thorac Oncol. 2010;5(1):69-74.

Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke. Waller LL, Miller AA, Petty WJ.. Lung Cancer. 2010;67(1):12-16.

Effects of continued tobacco use during treatment of lung cancer. Waller LL, Weaver KE, Petty WJ, Miller AA.. Expert Rev Anticancer Ther. 2010;10(10):1569-1575.

Overcoming pharmacokinetic resistance to erlotinib: rationale and preliminary findings from a phase II study [abstract]. Waller LL, Miller AA, Streer NP, McCoy TP, Petty WJ.. J Thorac Oncol. 2010;5(6 Suppl 3):S247-S248.

A novel prognostic transcriptional signature for early stage non-small cell lung cancer [abstract]. Ruiz J, Miller AA, Petty WJ, Chou JW, Miller LD.. J Thorac Oncol. 2010;5(12 Suppl 7):S505.

The tumor tissue renin-angiotensin system as a target for cancer therapy [abstract]. Petty WJ, Miller AA, Aklilu M, McCoy TP, Swift CB, Torti FM.. Int J Mol Med. 2010;26(Suppl 1):S19.

Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. Hughes AN, O'Brien MER, Petty WJ, Chick JB, Rankin E, Woll PJ, Dunlop D, Nicolson M, Boinpally R, Wolf J, et al.. J Clin Oncol. 2009;27(8):1220-1226.

Angiotensin-(1-7) inhibits triple negative tumor growth through the inhibition of angiogenesis and a reduction in placental growth factor PIGF [abstract]. Soto-Pantoja DR, Petty WJ, Gallagher PE, Tallant EA.. Cancer Res. 2009;69(2 Suppl):103S.

Incorporation of bevacizumab (B) and erlotinib (Er) with induction (I) and concurrent (C) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC) [abstract]. Socinski MA, Stinchcombe TE, Halle JS, Moore DT, Petty WJ, Blackstock AW, Gettinger SN, Decker RH, Khandani AH, Morris DE.. J Thorac Oncol. 2009;4(9 Suppl 1):S372-S373.

Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM.. Clin Cancer Res. 2009;15(23):7398-7404.

Comparison of expression and function of two functional RARbeta isoforms in human cancer: clinical implications for the differential splicing of the RARbeta gene [abstract]. Swift CB, Varela VA, Graves JT, Dmitrovsky E, Petty WJ.. Mol Cancer Ther. 2009;8(12 Suppl 1):A208.

Phase I study of angiotensin-(1-7), an endogenous antiangiogenic hormone: clinical, pharmacokinetic, and biomarker findings [abstract]. Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM.. Mol Cancer Ther. 2009;8(12 Suppl 1):B208.

Incorporation of bevacizumab (B) and erlotinib (Er) with induction (Ind) and concurrent (Conc) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC) [abstract]. Socinski MA, Stinchcombe TE, Halle JS, Moore DT, Petty WJ, Blackstock AW, Gettinger SN, Decker RH, Khandani AH, Morris DE.. J Clin Oncol. 2009;27(15 Suppl):7528.

Distinct functions of retinoic acid receptor beta isoforms: implications for targeted therapy. Swift CB, Hays JL, Petty WJ.. Endocr Metab Immune Disord Drug Targets. 2008;8(1):47-50.

Bi-directional translational research with angiotensin-(1-7) uncovers placental growth factor as a therapeutic target [abstract]. Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM.. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research ; 2008 Apr 12-16; San Diego (CA). Philadelphia (PA): AACR. 2008;():Abstr 4968.

Targeting the epidermal growth factor receptor in high-grade astrocytomas. Voelzke WR, Petty WJ, Lesser GJ.. Curr Treat Options Oncol. 2008;9(1):23-31.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Associate Professor, Hematology & Oncology

Clinical Interests

Lung Cancer, Thoracic Cancer
William Jeffrey Petty, M.D.

William Jeffrey Petty, M.D.

Associate Professor, Hematology & Oncology
Cancer Biology

Doctor Rating

4.7 out of 5

William Jeffrey Petty, M.D.117 Ratings
20 Comments


 

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.8
CP efforts to include in decisions
4.8
CP explanations of prob/condition
4.8
CP spoke using clear language
4.8
Friendliness/courtesy of CP
4.8
Likelihood of recommending CP
4.8
Patients' confidence in CP
4.8
Time CP spent with patient
4.8
Wait time at clinic
4.1



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

6/1/2016

Dr. Petty has been a blessing to myself and my wife. His compassion, understanding, and willingness to be there for me, helping me to understand the procedures, medicines and just a shoulder to lean on was a big help in getting me through this. Knowing that I mattered to him (not just as a patient but as a person) meant so much.

5/25/2016

I can't say enough good things about *Dr. Petty. He is the best. I feel so comfortable with him and he provides excellent care for me. He is a Godsend.

5/23/2016

Dr. Petty and PA Ghandi were AMAZING as always!!! We love them and trust them with my life!

5/11/2016

I hope I don't need to refer anyone else to Dr. Petty, but would do so with no hesitation.

5/5/2016

Dr. Petty is an outstanding professional in that he very personable, knowledgeable and caring.

5/5/2016

all good

4/30/2016

Dr. Petty was understanding and very informative - took time for myself and family members to understand

4/28/2016

I have complete confidence in *Dr. Petty. I ask his opinion on lots of things, and I take his advice. I truly believe that he cares about his patients on a level that few doctors do. One of the best!

4/21/2016

I love the way everyone took time to talk an care for me.

4/20/2016

You are a very lucky to have such a superb physician. He gave me my life back.

2/17/2016

#1-10. Excellent.

2/16/2016

How do you comment on a doctor that is almost as happy with your treatment results as you are. On this particular visit I was told that the chemo was a near completion and I really don't know who was smiling the most in that office, myself, my wife or Dr. Petty. He is an extremely good doctor, I have 100% confidence in his abilities and knowledge and consider myself lucky to have him taking care of me. THANK YOU DR. PETTY!

1/13/2016

Wonderful! *Dr. Petty is a wonderful doctor.

1/12/2016

Very impressed by his compassion & concern.

1/5/2016

Dr. Petty had treated me for a different issues a year or so back and upon finding out that I would need additional chemo for my lungs I ASKED for Dr. Petty because I have confidence in his ability and I trust him to do what is in my best interest and to keep me informed about my progress. I think Dr. Petty is a remarkable doctor and would recommend him to anyone.

1/5/2016

I have recommended Dr. Petty

10/28/2015

Quite pleasant experience!

10/27/2015

I have already recommended Dr. Petty and his team to others.

9/22/2015

I have recommended Dr. Petty and they think he is the BEST also.

8/24/2015

Very friendly.

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Magnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.